The role of ezetimibe in the prevention of cardiovascular disease: Where do we stand after ARBITER 6-HALTS

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 20, Issue 5, 2010, Pages 295-300

  Howard, Wm J ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Atherosclerotic cardiovascular disease; Dyslipidemia; Lipid lowering therapy

Indexed keywords

AZETIDINE DERIVATIVE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CLINICAL TRIAL; HUMAN; INTIMA; PATHOLOGY; TUNICA MEDIA;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; HUMANS; TUNICA INTIMA; TUNICA MEDIA;

EID: 77956696363     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.05.002     Document Type: Short Survey

References (16)

1. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults, executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
2. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
3. Smith S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113:2363-2372.
4. Wyne K.L. Metabolic syndrome: demographic features, etiology, and clinical management. Curr Atheroscler Rep 2005, 7:381-388.
5. Brunzell J.D., Davidson M., Furberg C.D., Goldberg R.B., Howard B.V., Stein J.H., et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008, 31:811-822.
6. Thavendiranathan P., Bagai A., Brookhart M.A., Choudhry N.K. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006, 166:2307-2313.
7. Davis H.R., Zetia Veltri E.P. Inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 2007, 14:99-108.
8. Robinson J.G., Davidson M.H., Shah A., Lin J., Neff D., DeLucca P.T., et al. Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65-74 and 75 years and older. Aging Health 2007, 3:691-705.
9. Kastelein J.J., Akdim F., Stroes E.S., Zwinderman A.H., Bots M.L., Stalenhoef A.F., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443.
10. Rossebø A.B., Pedersen T.R., Boman K., Brudi P., Chambers J.B., Egstrup K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356.
11. Peto R., Emberson J., Landray M., Baigent C., Collins R., Clare R., et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008, 359:1357-1366.
12. Taylor A.J., Villines T.C., Stanek E.J., Devine P.J., Griffen L., Miller M., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122.
13. Blumenthal R.S., Michos E.D. The HALTS trial-halting atherosclerosis or halted too early?. N Engl J Med 2009, 361:2178-2180.
14. Kastelein J.J., Bots M.L. Statin therapy with ezetimibe or niacin in high-risk patients. N Engl J Med 2009, 361:2180-2183.
15. Howard B.V., Roman M.J., Devereux R.B., Fleg J.L., Galloway J.M., Henderson J.A., et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008, 299:1678-1689.
16. Fleg J.L., Mete M., Howard B.V., Umans J.G., Roman M.J., Ratner R.E., et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008, 52:2198-2205.